RxDoctor Payments Data

Roxana Damian, PA

Physician Assistant · Sparks, NVNPI 1639740962

Payments from drug & device makers

$1,162in general payments, 2019–2025

Across 42 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$295
  • AbbVie$202
  • GSK$160
  • Gilead$107
  • Boehringer Ingelheim$91
  • Mannkind Corporation$78
  • plus $229 from 7 others

What the payments were for

  • Speaking & faculty fees$262%
  • Food & beverage$1,03689%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,162 in reported general payments places this provider in the 65th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$3,580
Medicare patients
41
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$17,886
TrulicityDulaglutide11$14,485
EliquisApixaban14$11,117
GemtesaVibegron14$6,537
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,808
Estradiol30$1,633
Gabapentin13$209
Atorvastatin Calcium46$198
Fluconazole17$189
Omeprazole25$185
Amlodipine Besylate38$155
Lisinopril33$132
Levothyroxine Sodium16$124
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$113
Losartan Potassium16$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$91$17,88620 claims
Lilly USA, LLCTrulicity$13$14,48511 claims
PfizerEliquis$16$11,11714 claims
Sumitomo Pharma America, Inc.Gemtesa$26$6,53714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →